Zealand boss must outperform Novo and Eli Lilly: "I'm not worried"
If Zealand Pharma gets its emergency treatment against low blood sugar approved by the FDA as expected, the company will face tough competition, but CEO Emmanuel Dulac believes he has the best product and is ready to prove it in trials.
Zealand Pharma had a good reason for popping open the champagne last week, as the company’s emergency treatment for critically low blood sugar, Hypopal, passed one last crucial study and became ready for an FDA evaluation.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
